Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioConsortia

Explore full profile

Agricultural biotechnology company that uses a proprietary method for the selection of

Davis, United StatesFounded 2014Food
Valuation $50–100M Last recorded · 2025
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for BioConsortia and the history behind them.

About BioConsortia

BioConsortia, Inc. operates as a research and development company at the forefront of agricultural biotechnology, focusing on microbial solutions to enhance crop yields and promote sustainability. Established in 2014, the company is the parent of BioDiscovery New Zealand, a firm founded in 1994 that developed the foundational technology. The decision to globalize under the BioConsortia name involved relocating headquarters to Davis, California, to better access U.S. markets and research opportunities.

Read full description

The company was significantly shaped by CEO Marcus Meadows-Smith. After a successful career in the agrichemical and biopesticide industry, including leading AgraQuest until its acquisition by Bayer CropScience for nearly $500 million, Meadows-Smith was drawn out of a brief retirement by the potential he saw in BioDiscovery's technology. He joined as CEO on the condition the company move to Davis, California, bringing his extensive experience in commercializing biological products for agriculture. The executive team includes other veterans from AgraQuest and Bayer CropScience, such as Christina Huben (SVP, Operations & Administration) and Dr. Hong Zhu (SVP, Research & Development), who collectively contribute decades of experience in the biologics sector.

BioConsortia's business model centers on developing advanced microbial products through to registration and then partnering with larger agricultural companies for commercialization and distribution. Revenue is generated through these strategic partnerships, which have included a major collaboration with The Mosaic Company to develop and launch nitrogen-fixing microbial products. This R&D-focused approach allows the company to concentrate on its core competency: discovery. The firm serves farmers globally across a wide array of crops, including corn, wheat, fruits, and vegetables, by providing solutions through its partners.

The core of BioConsortia's technical advantage lies in its patented Advanced Microbial Selection (AMS) process, a directed selection platform that rapidly identifies beneficial microbes. This system, combined with the GenePro genomics and gene-editing platform, allows scientists to discover and design microbes that enhance nitrogen fixation, control pests and diseases, and improve overall plant health. The product pipeline includes nitrogen-fixing microbes that reduce the need for synthetic fertilizers, biostimulants for yield enhancement, and biopesticides like fungicides and nematicides. A key feature of their products is the use of robust, spore-forming bacteria, enabling a shelf-life of over two years and on-seed viability for more than 18 months, which simplifies adoption for growers.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2014
Headquarters
Davis, United States
Employees
50
Open positions
None listed
Dealroom signal
39.0/100
Sub-industry
AgriTech
Sector
Food, Biotechnology, Crop Protection, Biopesticides, Synthetic Biology, Sustainable Development Goals, Biotech and Pharma, Regenerative Agriculture, Climate Tech, Hard Tech, DT and LS, science-based, nt
Business model
Manufacturing

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Aug 2025 $15M $60M Otter Capital ↗
LATE VCOther financing Apr 2024 $15M $60M Otter Capital ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

BioConsortia website traffic

Latest recorded traffic for BioConsortia is 1.5K monthly website visits, up 7.1% over the last three months. BioConsortia's team declined 2% over the past year.

Latest monthly visits1.5K 3-month web change+7.1% 1-year team growth-2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later2 investors entered at this stage

  • Square 1 Bank
  • Outset Ventures
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States95.7%
🇳🇿 New Zealand4.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BioConsortia on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioConsortia’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.